The Filing Desk

Bioventus vs TransMedics Group

Bioventus BVS · TransMedics Group TMDX · Health Care Equipment

TransMedics Group reported revenue of $606 million in fiscal 2025, about the same as Bioventus' $568 million in fiscal 2025. Bioventus' revenue fell 0.9% in its latest year, and TransMedics Group's grew 37.1%. Bioventus had an operating margin of 9.5%, against 17.9% at TransMedics Group. Free cash flow was $72 million at Bioventus and $134 million at TransMedics Group.

Side by side

BioventusTransMedics Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$568M$606M
Revenue growth−0.9%37.1%
Revenue growth a year, last 5 years12.1%88.3%
Gross margin68.3%59.9%
Operating margin9.5%17.9%
Net margin4.0%31.4%
Free cash flow$72M$134M
Free cash flow margin12.7%22.1%
Return on capital11.1%27.5%
Net debt to EBITDA2.5x−0.2x
Dividends and buybacks$0M$0M
Change in diluted share count6.8%15.1%
Last close$10.66$91.38
P/E at the last close13.3×25.0×
Insider trades, last 12 months—bought $1.1 million, sold $4.7 million
Piotroski F-score8 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BioventusTransMedics Group
Operating margin
Percent of revenue
BioventusTransMedics Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioventusTransMedics Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bioventus and TransMedics Group pages.